REFERENCES BIBLIOGRAPHIQUES
1. National Cancer Institute. What Is
Cancer? - NCI. National Cancer Institute. 2015.
https://www.cancer.gov/about-cancer/understanding/what-is-cancer
2. Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the
global cancer incidence and mortalityin2018: GLOBOCAN sources and methods.
Published online 2018. doi:10.1002/ijc.31937
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA
Cancer J Clin. 2019;69(1):7-34. doi:10.3322/CAAC.21551
4. WHO (World Health Organization). Cancer. 2018.
https://www.who.int/news-room/fact-sheets/detail/cancer
5. Sung H, Ferlay J, Siegel RL, et al. Global Cancer
Statistics2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36
Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.
doi:10.3322/CAAC.21660
6. Dy GW, Gore JL, Forouzanfar MH, Naghavi M, Fitzmaurice C.
Global Burden of Urologic Cancers, 1990-2013. EurUrol.
2017;71(3):437-446. doi:10.1016/J.EURURO.2016.10.008
7. Global Cancer Observatory. https://gco.iarc.fr/en
8. Group SB, Denny L, Adewole I, et al. On Behalf of the
Executive Council of the African Organisation for Research and Training in
Cancer (AORTIC).; 2013.
9. Burger M, Catto JWF, Dalbagni G, et al. Epidemiology and
riskfactors of urothelialbladder cancer. EurUrol. 2013;63(2):234-241.
doi:10.1016/J.EURURO.2012.07.033
10. Mostafa MH, Sheweita SA, O'Connor PJ. Relationship
betweenSchistosomiasis and Bladder Cancer. Clin MicrobiolRev.
1999;12(1):97. doi:10.1128/CMR.12.1.97
11. Cancer Today. https://gco.iarc.fr/today/en
12. Noncommunicablediseases Democratic Republic of the Congo 2018
country profile.
https://www.who.int/publications/m/item/noncommunicable-diseases-cod-country-profile-2018
13. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet
CC. Association between smoking and risk of bladder cancer among men and women.
JAMA. 2011;306(7):737-745. doi:10.1001/JAMA.2011.1142
14. Freedman ND, Leitzmann MF, Hollenbeck AR, Schatzkin A, Abnet
CC. Cigarette smoking and subsequentrisk of lung cancer in men and
women:analysis of a prospective cohortstudy. Lancet Oncol.
2008;9(7):649-656. doi:10.1016/S1470-2045(08)70154-2
15. Andreassen BK, Aagnes B, Gislefoss R, Andreassen M, Wahlqvist
R. Incidence and Survival of urothelialcarcinoma of the urinarybladder in
Norway 1981-2014. BMC Cancer. 2016;16(1).
doi:10.1186/S12885-016-2832-X
16. Gryseels B, Polman K, Clerinx J, Kestens L. Human
schistosomiasis. Lancet. 2006;368(9541):1106-1118.
doi:10.1016/S0140-6736(06)69440-3
17. Hotez PJ, Molyneux DH, Fenwick A, et al. Control of Neglected
Tropical Diseases. New England Journal of Medicine.
2007;357(10):1018-1027.
doi:10.1056/NEJMRA064142/ASSET/03E9D853-E92D-4DEA-8053-6124F8C32F91/ASSETS/IMAGES/LARGE/NEJMRA064142_T3.JPG
18. J. GAUD. LES BILHARZIOSES EN AFRIQUE OCCIDENTALE ET EN
AFRIQUE CENTRALE.
https://iris.who.int/bitstream/handle/10665/265545/PM538005.pdf.
19. World Health Organization. Ending the Neglect to Attain
the SustainableDevelopment Goals?: A Road Map for Neglected Tropical Diseases
2021-2030. World Health Organization; 2021.
20. Van Der Werf MJ, De Vlas SJ, Brooker S, et al. Quantification
of clinicalmorbidityassociatedwith schistosome infection in sub-SaharanAfrica.
Acta Trop. 2003;86(2-3):125-139. doi:10.1016/S0001-706X(03)00029-9
21.
https://anafrimed.net/eco-epidemiologie-de-schistosomiase-a-schistosoma-mansoni-zone-de-sante-rurale-de-kimpese-de-2011-2015-eco-epidemiology-of-schistosomiasis-in-schistosoma-mansoni-in-the-rural-health-area/.
22. Mustacchi P. Schistosomiasis and Cancer of the Bladder.
Published online 2003. https://www.ncbi.nlm.nih.gov/books/NBK13949/
23. Mamadou Diallo. PLACE DE LA BILHARZIOSE URINAIRE LES
TUMEURS DE VESSIE AU SERVICE'UROLOGIE DU CENTRE HOSPITALIER UNIVERSITAIRE
TOURÉ.; 2003.
https://bibliosante.ml/bitstream/handle/123456789/7555/03M21.pdf?sequence=1
24. Ishida K, Hsieh MH.
Understandingurogenitalschistosomiasis-relatedbladdercancer: An update.
Front Med (Lausanne). 2018;5(AUG):373022.
doi:10.3389/FMED.2018.00223/BIBTEX
25. Colley DG, Bustinduy AL, Secor WE, King CH. Human
schistosomiasis. The Lancet. 2014;383(9936):2253-2264.
doi:10.1016/S0140-6736(13)61949-2
26. Khaled H. Schistosomiasis and Cancer in Egypt:Review. J
Adv Res. 2013;4(5):461. doi:10.1016/J.JARE.2013.06.007
27. Botelho MC, Machado JC, da Costa JMC. Schistosoma haematobium
and bladdercancer:What lies beneath? Virulence. 2010;1(2):84-87.
doi:10.4161/VIRU.1.2.10487
28. Mustacchi P. Schistosomiasis and Cancer of the Bladder.
Published online 2003. https://www.ncbi.nlm.nih.gov/books/NBK13949/
29. Rouprêt M, Neuzillet Y, Pignot G, et al.
Recommandations françaises du Comité de Cancérologie de
l'AFU - Actualisation 2018-2020 : tumeurs de la vessie. Progres
en Urologie. 2018;28:S46-S78. doi:10.1016/j.purol.2018.07.283
30. Parkin DM. The global healthburden of infection-associated
cancers in the year 2002. Int J Cancer. 2006;118(12):3030-3044.
doi:10.1002/IJC.21731
31. Bedwani R., Renganathan E EKFBCASHAATZAFSBPLVC.
Schistosomiasis and the risk of bladder cancer in Alexandria, Egypt. Br J
Cancer. Published online 1998. doi:10.1038/bjc.1998.197
32. Bilharziose - MedG. https://www.medg.fr/bilharziose/
33. Risques de cancer de la vessie | Société
canadienne du cancer.
https://cancer.ca/fr/cancer-information/cancer-types/bladder/risks
34. Christophe Lelubre MD P. Les études
comparatives non randomisées. Published online 2020.
http://www.pneumocancero.com/Medecine_factuelle/2019-2020/08.%20Lelubre.pdf
35. Saint Pierre P. Epidémiologie. Published online 2021.
moz-extension://274a8b8f-0d0a-4d34-b3ab-b90646719e4c/enhanced-reader.html?openApp&pdf=https%3A%2F%2Fperso.math.univ-toulouse.fr%2Fpsaintpi%2Ffiles%2F2021%2F04%2FFormation_Epidemiologie_Part_3.pdf
36. Critique les résultats d'une étude - LEPCAM.
https://lepcam.fr/index.php/les-etapes/critique/
37. Case-Control Studies: Design, Conduct, Analysis - James J.
Schlesselman - Google Livres.
https://books.google.be/books?hl=fr&lr=&id=5OkyFkYOn0QC&oi=fnd&pg=PA3&dq=1.+Schlesselman+JJ.+Case-Control+Studies:+Design,+Conduct,+Analysis.+Oxford+University.+Press%3B+1982.&ots=phbfd2ZDBt&sig=ZF7wJUfLi22zTuIrOTD0g1w6PzQ#v=onepage&q&f=false
38. Humans IWG on the E of CR to. IARC MONOGRAPHS. IARC
Monogr Eval Carcinog Risks Hum. 1994;61:121-162.
https://www.ncbi.nlm.nih.gov/books/NBK487783/
39. Botelho MC, Machado JC, da Costa JMC. Schistosoma haematobium
and bladdercancer:What lies beneath? Virulence. 2010;1(2):84-87.
doi:10.4161/VIRU.1.2.10487
40. Rapport d'un Comité d'experts de l'OMS. SCHISTOSOMIASE
ET GÉOHELMINTHIASES: PRÉVENTION ET LUTTE. Published online 2002.
https://iris.who.int/handle/10665/42880
41. Vennervald BJ, Polman& K. Helminths and malignancy.
Published online 2009. doi:10.1111/j.1365-3024.2009.01163.x
42. inobaya MT, Olveda RM, Chau TN, Olveda DU, Ross AG, Ross A.
Prevention and control of schistosomiasis:acurrent perspective. Published
online 2014. doi:10.2147/RRTM.S44274
43. WORLD HEALTH ORGANIZATION INTERNATIONAL AGENCY FOR RESEARCH
ON CANCER. WORLD HEALTH ORGANIZATION IARC MONOGRAPHS ON THE EVALUATION OF
CARCINOGENIC RISKS TO HUMANS. IARC MONOGRAPHS. Published online
1996.
44. Preventive in humanhelminthiasischemotherapy. Published
online 2006.
45. Siemiatycki J, Dewar R, Nadon L, Gérin M.
Occupationalriskfactors for bladdercancer:resultsfrom a case-control study in
Montreal, Quebec, Canada. Am J Epidemiol. 1994;140(12):1061-1080.
doi:10.1093/OXFORDJOURNALS.AJE.A117207
46. Messing EM, Vaillancourt A. Hematuria screening for bladder
cancer. J Occup Med. 1990;32(9):838-845.
doi:10.1097/00043764-199009000-00016
47. Heney NM, Ahmed S, Flanagan MJ, et al.
Superficialbladdercancer: progression and recurrence. J Urol.
1983;130(6):1083-1086. doi:10.1016/S0022-5347(17)51695-X
48. Prout GR, Griffin PP, Shipley WU. Bladdercarcinoma as a
systemicdisease. Cancer. 1979;43(6):2532-2539.
doi:10.1002/1097-0142(197906)43:6<2532::aid-cncr2820430654>3.0.co;2-b
49. BLOOM HJG, HENDRY WF, WALLACE DM, SKEET RG. Treatment of T3
bladdercancer:controlled trial of pre-operativeradiotherapy and radical
cystectomy versus radical radiotherapy. Br J Urol. 1982;54(2):136-151.
doi:10.1111/J.1464-410X.1982.TB13537.X
50. Filella X, Molina R, Ballesta AM, et al. Value of PSA
(prostate-specificantigen) in the detection of prostate cancer in patients
withurologicalsymptoms. Results of a multicentrestudy. Eur J Cancer.
1996;32A(7):1125-1128. doi:10.1016/0959-8049(96)00092-5
51. Barton MB, Frommer M, Shafiq J. Role of radiotherapy in
cancer control in low-income and middle-income countries. Lancet
Oncol. 2006;7(7):584-595. doi:10.1016/S1470-2045(06)70759-8
52. James ND, Hussain SA, Hall E, et al. Radiotherapywith or
withoutchemotherapy in muscle-invasive bladder cancer. N Engl J Med.
2012;366(16):1477-1488. doi:10.1056/NEJMOA1106106
53. Little RJA, Rubin DB. Statisticalanalysiswithmissing data.
StatisticalAnalysiswithMissing Data. Published online January 1,
2019:1-449. doi:10.1002/9781119482260
| 
